[Bausch Health Companies Q3 2026 Earnings Call] Bausch Health Raises Guidance Again as Quarterly Adjusted EBITDA Tops $1 Billion for First Time; Warns of $400–$500 Million XIFAXAN Headwind in 2027
Bausch Health (BHC) reported Q3 2026 revenue of $2.94B, up 10% YoY, with adjusted EBITDA surpassing $1B for the first time. The company raised full-year guidance but warned of $400M-$500M XIFAXAN headwind in 2027 due to Medicare rebates. Salix segment grew 16%, driven by XIFAXAN. Net debt reduced by $1B YTD, with plans for debt redemptions and share repurchases.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to drive short‑term buying pressure, while the disclosed 2027 XIFAXAN rebate headwind may temper longer‑term enthusiasm.
Market read
The report adds fresh earnings data and guidance for a mid‑cap pharma stock, influencing sector sentiment and potentially prompting re‑rating by analysts.
What to watch
Potential impact of upcoming regulatory changes on specialty drug pricing and the integration risks of the China distributor acquisition.
Background
Bausch Health Companies Inc. (NYSE:BHC) delivered its strongest quarterly performance since the Bausch + Lomb IPO, with revenue up 10% YoY and adjusted EBITDA surpassing $1B for the first time.
Ticker impact
Bausch Health reported Q3 2026 results with adjusted EBITDA over $1B and raised full-year guidance, while warning of a $400‑$500M XIFAXAN headwind in 2027.
likely modest upside as investors price in higher 2026 guidance, tempered by downside pressure from the XIFAXAN 2027 headwind
Earnings beat and guidance lift are fresh primary information; market typically reacts positively to raised guidance, though the noted headwind introduces caution.
Market effects
Strengthens outlook for the broader pharma/healthcare sector as a large player shows robust growth, but highlights potential pricing pressure on specialty drugs.
Positive impact on North American healthcare indices; limited effect on emerging markets.
Adds to global pharma earnings momentum, may influence investor sentiment toward other specialty drug firms.
Counterpoint
The XIFAXAN headwind could signal deeper pricing challenges, suggesting the guidance raise may be overstated.
Key entities
- ExecutiveThomas Appio
CEO of Bausch Health, provided commentary on earnings and guidance.
- ExecutiveJJ Charhon
CFO, detailed financial metrics and headwind estimates.
